A strong market for biosimilar medicines drives commercial competition and offers a greater choice of affordable biological treatments.
Across the NHS, demand for high-cost disease modifying medicines is increasing. The competition in the biological medicines market brought about by the entry of biosimilar medicines stimulates innovation and encourages all manufacturers to increase the value of their offer to the NHS. Early adoption and widespread use of biological medicines offering improved value to the NHS frees up resources so that many more patients benefit from reinvestment in services and improved access to newer innovative therapies.
This strategy sets out the steps the NHS and its partners in Wales will take to support the conditions needed to create a strong, competitive biological and biosimilar medicines’ market in the UK benefiting the NHS, patients and the economy of Wales.
⇩ Maximising the opportunity presented by biosimilar medicines - A national strategy for Wales 355KB (PDF) |
(Published January 2023)